NVHR Hepatitis B Public Comments

Share this

NVHR executive director Ryan Clary provided public comments at a FDA Advisory Committee meeting on July 28, 2017. Clary highlighted the unmet need in hepatitis B prevention, focusing on the disproportionate impact of hepatitis B on Asian Americans and Pacific Islanders, the alarming increase in hepatitis B infections among people who inject drugs, and the goal of eliminating the public health threat of hepatitis B by 2030.